News ESMO26: Ris-rez offers hope of osteosarcoma breakthrough There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.
News ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforces earlier results in platinum-resistant ovarian cancer.
News Roche offers $15bn for strategic-level deal with Hansoh A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more than 10 times larger.
News Data reveal is promising for GSK's lung cancer drug ris-rez The first data from GSK's international trial of B7-H3-targeted ADC ris-rez in small cell lung cancer back up earlier results from a Chinese study.
News GSK showcases positive data with lung cancer drugs at WCLC New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.
News GSK bags breakthrough status for bone cancer drug GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.